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We tried to develop a dual-modal PET/MR imaging probe using a straightforward one-pot method by encapsulation with specific
amphiphiles. In this study, iron oxide (IO) nanoparticles were encapsulated with three amphiphiles containing PEG, DOTA and the prostate-
specific membrane antigen (PSMA)-targeting ligand in aqueous medium. The diameter of the prepared nanoparticle DOTA-IO-GUL was
11.01 ± 1.54 nm. DOTA-IO-GUL was labeled with 68Ga in high efficiency. The DOTA-IO-GUL showed a dose-dependent binding to
LNCaP (PSMA positive) cells via a competitive binding study against 125I-labeled MIP-1072 (PSMA-targeting agent). Additionally, PET
and MR imaging results showed PSMA selective uptake by only 22Rv1 (PSMA positive) but not PC-3 (PSMA negative) in dual-tumor
xenograft mouse model study. MR imaging showed high resolution, and PET imaging enabled quantification and confirmation of the
specificity. In conclusion, we have successfully developed the specific PSMA-targeting IO nanoparticle, DOTA-IO-GUL, as a dual-modality
probe for complementary PET/MR imaging.
From the Clinical Editor: The combination of using Positron Emission Tomography (PET) and computed tomography (CT) in clinical
practice is now the norm. With advances in technology, the next step would be to develop combined PET and Magnetic Resonance (MR)
dual-imaging. In this article, the authors described their positive study on the development of a dual-modal PET/MR imaging probe using a
prostate cancer model.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and magnetic resonance (MR) dual-imaging emerged as an
important topic in nuclear medicine and molecular imaging
studies.1-6 PET/computed tomography (CT) was developed for
its complementary effect of using both PET and CT imaging,
which replaced most PET-only instruments. Because of the
higher sensitivity and specificity of MR imaging compared with
CT, PET/MR dual-imaging is expected to be the next generation
of PET/CT.7-12 Thus, the development of a probe for PET/MRFunding sources: National Research Foundation of Korea (NRF-
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synergistic instrument. Recently, PET/MRI agents are produced
by using various materials such as Gd, Cu, Zr, iron oxide,
etc.13-17 These PET/MRI agents are used for T1 or T2 imaging
according to function and characteristics of each material.
Nanoparticles (NP) are widely studied for their use as
imaging probes,18,19 especially because they have a large surface
area relative to volume or diameter, which allows them to
introduce special ligands and multiple beacons for targeting and
imaging.20,21 Various surface modification methods have been
investigated to produce multimodal imaging NPs, most of which
included step-by-step modification using chemical reactions and
purification. However, these methods have intrinsic drawbacks
such as low yield and poor reproducibility.22,23 A novel,
straightforward encapsulation method producing high yield and
high reproducibility has been reported24-27: in this method, NPsT/MR dual-modal imaging probe for targeting prostate-specific membrane
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by vortexing, heating and sonication. This method could easily
be applied to various kinds of NPs with hydrophobic surface,
such as quantum dots, iron oxide, gold, etc.
Iron oxide (IO) NPs have been actively investigated as MRI
contrast agents in clinical trials.28-33 Furthermore, they have also
been applied as PET/MR dual imaging probes after being labeled
with positron emitters.9,12,25,34
68Ga is a well-known positron emitter having an adequate
half-life for diagnostic imaging (68 min), and is produced by a
68Ge/68Ga-generator which has huge economical and technical
merits.35,36 Bifunctional chelating agents are essential for
labeling NPs with 68Ga.37-39 The 1,4,7,10-tetraazacyclododeca-
ne-1,4,7,10-tetraacetic acid (DOTA) is one of the most widely
used bifunctional chelating agents.40 Particularly, DOTA could
be used for both diagnostic radioisotopes such as 68Ga and 111In,
and therapeutic radioisotopes such as 90Y and 177Lu, which is
important for the theranostic use of NPs.
Prostate cancer is one of the most common types of cancer in
the world.41,42 The prostate specific membrane antigen (PSMA)
is a well-known biomarker of prostate cancer, therefore many
PSMA targeting molecules have been developed and
investigated.43 -48 Furthermore, the glutamate-urea-lysine
(GUL) conjugate has been proven to be a PSMA targeting
moiety and its 3D structure has also already been published.49
In this study, we aim to develop a new PSMA-targeting IO
NP for use in PET/MR dual-imaging. To achieve this, we
employed the encapsulation method using amphiphiles contain-
ing DOTA and GUL each conjugated with a long alkyl chain and
commercially available IO NP. The DOTA moiety was used for
labeling with 68Ga and the GUL moiety was used for targeting
PSMA. The IO core was used for MR imaging.Methods
General remarks
Oleic acid-coated IO NP in chloroform was purchased from
MKnano (MK Implex Corp., ON, Canada). The hydrodynamic
diameter and size distribution of nanoparticles were analyzed
using the DLS system from Zetasizer Nano ZS90 (Malvern
Instruments Ltd., Worcestershire, UK) and transmission electron
microscope (TEM) imaging using the JEM-1400 electron
microscope (JEOL Ltd., Tokyo, Japan). A SCINCO S-3100
was used for UV/vis spectrometer (SCINCO America, WI,
USA). The 68Ge/68Ga-generator was purchased from ITG (ITG
GmbH, Munich, Germany). Instant thin layer chromatography-
silica gel (ITLC-SG) was purchased from Agilent Technologies,
Inc. (CA, USA). Radio-TLC was counted using a Bio-Scan
AR-2000 System imaging scanner (Bioscan, WI, USA). Animal
PET/CT imaging was performed using the eXplore Vista PET/
CT scanner (GE Healthcare, CT, USA). Animal PET imaging
was performed using the G4 PET X-RAY scanner (Sofie
Biosciences, Culver City, CA, USA).The Agilent 9.4T 160/AS
MRI system and millipede coil (both radiofrequency transmis-
sion and signal reception) (Agilent Technologies, Santa Clara,
CA, USA) were used for the MRI system.All animal studies were performed at the Seoul National
University Hospital, Seoul, Korea, which is fully accredited by
AAALAC International (2007, Association for Assessment and
Accreditation of Laboratory Animal Care International).Preparation of the DOTA-IO-GUL nanoparticle
The DOTA-SA (2.57 mg, 3.19 μmol) and GUL-SA
(3.27 mg, 3.19 μmol) were suspended in a solution of 8%
Tween® 60 in distilled water (v/v, 1 mL) in a 2-mL glass vial.
The reaction mixture was sonicated for 30 min using the
ultrasonicator (77.8 W, amplitude = 70%, cycle = 1). Then, IO
in chloroform (5 mg/mL, 100 μL) was slowly added. The
reaction mixture was sonicated for 10 min and heated to 80 °C
for 10 min. This step was repeated 3 times to remove
chloroform. After removing the chloroform, the reaction mixture
was sonicated for 2 h (77.8 W, amplitude = 70%, cycle = 1).
Finally the reaction mixture was changed to clear dark brown
color solution. The reaction mixture was purified by Sephacryl®
S-500 HR-packed column chromatography (14.5 × 150 mm,
V0 = 2.37 mL) using distilled water as an eluent. The clean
brown fractions were collected and concentrated by ultra-
filtration (Amicon Ultra-0.5, 100 kDa, 5000 G, 30 °C, 5 min).Size analysis
DOTA-IO-GUL hydrodynamic diameter, size distribution
and zeta potential were measured by the DLS instrument. Sample
DOTA-IO-GUL (10 μL) was dissolved in distilled water
(1 mL). This prepared sample was measured in a cuvette for
DLS. The measured particle size and distribution were obtained
in number-percent (%) value at 25 °C at a scattering angle of 90°.
Zeta potential was also measured by the DLS.
TEM was used for shape examination and size confirmation.
Samples were diluted 100 times using distilled water and were
dropped into the Ni coated metal grid. TEM images were
obtained using an acceleration voltage of 80 keV.Ferric ion concentration analysis
The Fe concentration of encapsulated DOTA-IO-GUL was
analyzed using the iron thiocyanate colorimetric method. This
method was based on Beer's law plot of iron(III) thiocyanate
absorbance at 481 nm. Various concentrations of Fe(NO3)3
standard (0.1, 0.08, 0.06, 0.04, and 0.02 M), 0.5 M nitric acid
and 1 M potassium thiocyanate solutions were prepared. Each
5 μL aliquot of Fe(NO3)3 and sample DOTA-IO-GUL solution
was mixed with 1 mL of 0.5 M nitric acid solution. The mixture
was incubated for 30 min at room temperature, and then 1 mL of
1 M potassium thiocyanate was added to each mixture. After
vortexing, the mixture was incubated for 30 min at room
temperature. The absorbance of the resulting Fe(SCN)2+
solution at 481 nm was measured by the UV–vis spectropho-
tometer. The standard equation of standard Fe3+ concentration
versus absorbance at 481 nm was drawn from the data by linear
regression. The Fe3+ concentration of DOTA-IO-GUL was
obtained from the equation and the absorbance of the sample.
Figure 1. (A) Encapsulation of NPs with specific amphiphiles. (B) Diagram of encapsulated DOTA-IO-GUL.
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The stability of DOTA-IO-GUL in a high salt solution was
tested by the incubation of DOTA-IO-GUL in 0.9%, 1.8% and
3.6% NaCl (w/v) aqueous solution. These mixtures were
incubated at room temperature and NP sizes were measured by
DLS at 1 h, 12 h and 24 h.
68Ga labeling
68GaCl3 (111 MBq) in 0.1 M HCl solution (200 μL) was
added to 1 M sodium acetate buffer (pH = 5.6, 200 μL).
DOTA-IO-GUL (20 μL) was added and vortexed for 1 min.
The reaction mixture was incubated for 30 min at 90 °C and was
then cooled to room temperature. The labeling efficiency of
68Ga-DOTA-IO-GUL was measured by ITLC-SG eluted with
0.1 M citric acid and scanned by the radio-TLC scanner. The
medium of 68Ga-DOTA-IO-GUL solution was replaced with
distilled water by centrifugal ultrafiltration (0.4 mL, 3 times) and
concentrated to 100 μL using the Amicon tube by centrifugation.Stability test in serum
68Ga-DOTA-IO-GUL (3.7 MBq, 100 μL) was added to
human serum (1 mL) and was then vortexed vigorously. The
mixture was incubated in a shaking incubator at 37.5 °C. After
2 h, the radiochemical purity of the reaction mixture was tested
by radio-TLC as described above. We also compared the gel
filtration (Sephacryl® S-500 HR; column: 14.5 × 150 mm)
elution profiles of 68Ga-DOTA-IO-GUL before and after the
incubation with human serum.
Human prostate cancer cell culture
Two PSMA-positive prostate cancer cell lines, 22Rv1 and
LNCaP, and one PSMA-negative prostate cell line, PC-3, were
used for this study. All prostate cancer cell lines were grown in a
humidified incubator with a 5% carbon dioxide supply at 37 °C.
The 22Rv1 cell line was purchased from ATCC and was grown
in ATCC-formulated RPMI 1640 (WELGENE Inc., Korea)
mixed with 10% (v/v) heat inactivated fetal bovine serum (FBS)
Figure 2. Size determination of DOTA-IO-GUL. (A) DLS data of
DOTA-IO-GUL (d = 11.01 ± 1.541 nm). (B) TEM image of DOTA-IO-GUL.
Figure 3. DOTA-IO-GUL stability study in 0.9%, 1.8% and 3.6% NaCl
solutions for 1 h, 12 h and 24 h. (B) 68Ga-DOTA-IO-GUL stability study in
human serum for 2 h at 36.5 °C. (C) 68Ga-DOTA-IO-GUL stability study in
human serum for 2 h at 36.5 °C.
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antibiotic-antimycotic (100×) (Gibco®, Life Technologies
Korea, Korea). The LNCaP and PC-3 cell lines were purchased
from the Korean Cell Line Bank (KCLB, Seoul, Korea). The
LNCaP cell culture was grown in minimum essential medium
(MEM) (Gibco®, Life Technologies Korea, Korea) mixed with
10% (v/v) heat-inactivated FBS containing 1% (v/v) antibioti-
c-antimycotic (100×). The PC-3 cells were cultured in the same
medium used for the 22Rv1 cell line.
In vitro competitive cell binding assay
LNCaP and PC-3 cells were used for competition binding
analysis as PSMA-positive and PSMA-negative cell lines,
respectively. The cells were plated in 24-well plates at
approximately 2 × 105 cells/well and incubated for 24 h in a
humidified incubator at 37 °C with 5% CO2 supply. DOTA-IO-
GUL was serially diluted in a serum-free cell culture medium
containing 0.5% bovine serum albumin. Each 0.5 mL of the
diluted DOTA-IO-GUL sample was added to the cells with
1.85 kBq/0.5 mL of 125I labeled (S)-2-(3-((S)-1-carboxy-5-
((4-iodobenzyl)amino)pentyl)ureido)pentanedioic acid (125I-
MIP-1072)50 and incubated for 1 h in a humidified incubator
at 37 °C with 5% CO2. After 1 h, the media were aspirated and
the pellet was washed twice by dispersal in fresh assay medium
cells. One mL of 1% sodium dodecyl sulfate in phosphate
buffered saline was added to each well and gently mixed todissolve cells. The dissolved cells were transferred to 5-mL
plastic test tubes. Radioactivity was counted by a gamma
scintillation counter.
Establishing a xenograft model
Specific pathogen-free 4-week old male BALB/c nude mice
were used for all animal studies. 5 × 106 cells each of the 22Rv1
and PC-3 cell lines in 0.1 mL of RPMI-1640 medium were
subcutaneously injected into the left and right flanks of mice,
respectively. The xenografted tumors were grown for 2-3 weeks
and then the mice were used for in vivo imaging studies.
PET imaging study in mouse xenograft model
68Ga-DOTA-IO-GUL in normal saline (10.2 MBq, 100 μL)
was injected into the 22Rv1 xenograft mice via the tail vein.
After 1 h, images of the mice were obtained by static mode for
10 min under isoflurane anesthesia. These PET images were
acquired by 3-dimensional Fourier re-binning using a 2-
dimensional ordered-subsets expectation maximization recon-
struction algorithm using the MMWKS-Vista software. For each
PET scan, 3-dimensional regions of interest (ROI) were drawn
over tumors on whole-body axial images. Standardized uptake
values (SUV) were obtained using reconstructed data for each
PET imaging system.
MRI imaging study in mouse xenograft model
A phantom study was performed to prove the dose-dependent
MR signal acquisition. T2-weighted images were obtained using
a phantom prepared with PCR tubes containing serially diluted
DOTA-IO-GUL (200, 100, 50.0, 25.0, 12.5, 6.25 and 3.13 μM
of ferric ion) in agarose solution. For animal MR imaging,
22Rv1 and PC-3 xenografted mice were used. The control MR
image was obtained before the DOTA-IO-GUL injection in
anesthesia by isoflurane/O2 (2% isoflurane, 1.0 L/min oxygen).
The T2-weighted image was measured in fast spin echo multiple
slice (FSEMS) pulse sequence. The retention time was 3000 ms
and the effective echo time was 29.0 ms. Echo train length (ETL)
was 4, and the average was also 4. The matrix was 192 × 192
Figure 5. In vitro cell binding assay result. Bound radioactivity of
125I-MIP-1072, a PSMA-inhibitor, to the PSMA-positive cells, LNCaP,
showed a dose-dependent decrease by addition of DOTA-IO-GUL.
Figure 4. 68Ga-DOTA-IO-GUL stability study in human serum for 2 h at
36.5 °C. (A) Radiochemical purity (%) of 68Ga-DOTA-IO-GUL checked by
ITLC after incubation in human serum. (B) Elution profiles of
68Ga-DOTA-IO-GUL control and 2 h after incubated 68Ga-DOTA-
IO-GUL in human serum determined by the Sephacryl® S-500 HR gel
filtration chromatography.
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18.0 × 35.0 mm2. The slices were 15 and slice thickness was
1.00 mm. After completion of the control MR imaging study,
DOTA-IO-GUL 200 μM in 0.1 mL normal saline was injected
into the tail vein of the mice. After 1 h, the T2-weighted MR
image was obtained through the same method as control mice
imaging. These MRI results were analyzed using the Sante
DICOM viewer program.Results
Preparation of IO NPs
The specific amphiphiles (S)-2-(3-((S)-1-carboxy-5-
stearamidopentyl)ureido)pentanedioic acid (GUL-SA) and
2,2′,2″,2‴-(2-(4-(3-octadecylthioureido)benzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA-
SA) were synthesized by 2- and 1-step reactions with 45% and
36% yields, respectively (supplementary material Schemes S1
and S2). These amphiphiles were used for the encapsulation of IO
core. The encapsulated NP DOTA-IO-GUL, a dark brown liquid,
was obtained using the schematic methodwith a final yield if 85%
(Figure 1, A). The prepared DOTA-IO-GUL has an IO core and a
functionalized capsule composed of polysorbate 60, DOTA-SA
and GUL-SA (Figure 1, B). Polysorbate 60 provides a
polyethyleneglycol (PEG) side chain which allows it to escape
from the immune system, known as the “stealth effect”. The
DOTA moiety is used for radiolabeling with metallic a
radioisotope (68Ga in this study) and the GUL moiety is used
for targeting PSMA. The diameter of DOTA-IO-GUL, measured
by dynamic light scattering (DLS), was 11.01 ± 1.541 nm
(Figure 2, A), which was confirmed by transmission electron
microscopy (TEM) imaging (Figure 2, B).
Radiochemistry
The DOTA-IO-GUL was labeled with 68Ga in a sodium
acetate buffer (pH 5.6), with over 99% efficiency. According to
radio thin layer chromatography (TLC) (ITLC-SG: solid phase,
0.1 M citric acid: mobile phase), 68Ga-DOTA-IO-GUL
remained at the origin (Rf = 0.0) and free
68Ga moved with
the solvent front line (Rf = 1.0). The medium of the radiolabeled
mixture was replaced with distilled water by centrifugal
ultrafiltration and then concentrated to 100 μL for the following
experiments. The radiochemical purity of the final purified
68Ga-DOTA-IO-GUL was higher than 99% (supplementary
material Figure S1).
Stability tests
NPs tend to aggregate in high salt solution which is one of the
most common stability problems of NPs. In order to test the
stability of DOTA-IO-GUL, it was incubated with various
concentrations of NaCl aqueous solutions (0%, 0.9%, 1.8%, and
3.6%) for 24 h. Then the particle sizes of the solutions were
measured using dynamic light scattering (DLS) to check for
aggregation at 1, 12 and 24 h post-incubation (Figure 3).
The results revealed that DOTA-IO-GUL size did not show
any significant changes in the above conditions. This
Figure 6. MRI phantom study for the determination of DOTA-IO-GUL injection concentration. (A) MR image was obtained from serially diluted
DOTA-IO-GUL from 200 μM Fe3+ concentration. (B) Calculation of r2 relaxivity coefficient value of DOTA-IO-GUL (y = 185.13 x + 2.6898; R
2 = 0.9968).
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salt solutions that are even 4-times more concentrated than
physiological condition.
After being labeled with 68Ga, the 68Ga-DOTA-IO-GUL was
incubated in human serum at 37 °C with shaking. The stability
was checked by radio TLC after 2 h of incubation as mentioned
in the experimental section, and found to have 94% stability
(Figure 4, A, supplementary material Figure S1c). Additionally,
we compared the elution profiles of 68Ga-DOTA-IO-GUL before
and after 2 h incubation in human serum using Sephacryl® S-500
HR gel filtration chromatography (Figure 4, A). The result showed
no significant change of elution profile, which proved that the
68Ga-DOTA-IO-GUL nanoparticle was stable in human serum at
36.5 °C.
According to these in vitro experimental results, we found that
68Ga-DOTA-IO-GUL is stable enough to be used as a PET probe.
Competitive binding study using a PSMA-positive cell line
Specific binding of DOTA-IO-GUL to PSMA-positive cells
was confirmed by an in vitro competitive binding study. A
previously reported PSMA-imaging agent, 123I-MIP-1072, was
used as a radiolabeled ligand.50,51. The PSMA-positive
human prostate cancer cell line, LNCaP, was incubated with
125I-MIP-1072 and various concentration of DOTA-IO-GUL at
room temperature for 1 h. After the aspiration of unbound
fractions, the cell-bound radioactivities were measured. A
binding curve with dose-dependent blocking was obtained
(Figure 5), which proved the specific binding of DOTA-IO-GUL
to PSMA-positive cells.
In vivo imaging study using a xenograft model
MR imaging of a phantom composed of serially diluted aqueous
solutions of 200 μMDOTA-IO-GUL demonstrated the linearity of
T2-weighted MR signal with IO concentrations (Figure 6).For in vivo imaging studies, a BALB/c mouse model having
prostate cancer xenografts of the PSMA-positive cell line (22Rv1)
and PSMA-negative cell line (PC-3) at the left and right flank,
respectively, was established. Both of the 22Rv1 and PC-3 tumor
MR images taken before administration of NOTA-IO-GUL were
shown to be white masses (Figure 7, A). However, decreased MR
signals (as block dots) were found with the 22Rv1 tumor,
representing increased uptake of IO NPs after an injection of
DOTA-IO-GUL, while the PC-3 tumor did not show any change.
This result demonstrated that DOTA-IO-GUL was only taken up
by the PSMA-positive 22Rv1 tumor and not by the PSMA-
negative PC-3 tumor (Figure 7, B). However, this MR imaging
study could not provide quantitative information on tumor uptake.
PET images were obtained 1 h post-injection of
68Ga-DOTA-IO-GUL through the tail vein, and the uptake of
68Ga-DOTA-IO-GUL was found only in the 22Rv1 tumor,
which was consistent with the MR imaging study (Figure 8, A).
However, the resolution of PET images was much lower than
MR images. The obviously dotted MR images showed localized
distribution in the tumor with higher resolution than PET. On the
other hand, the PSMA-specific uptake could be proved by a
blocking study in vivo using PET imaging. A known
PSMA-specific small molecule, MIP-1072, was co-injected with
68Ga-DOTA-IO-GUL through the tail vein, and it was found that
68Ga-DOTA-IO-GUL uptake was blocked (Figure 8, B). The
specific uptake of 68Ga-DOTA-IO-GUL by the PSMA-positive
tumor was proven by these results.
In addition, the PET imaging study could be used for the
quantification of tumor uptakes. The amount of the injected
68Ga-DOTA-IO-GUL was 1.544 μg. The standard uptake value
(SUV) of the 22Rv1 tumor was calculated as 2.385 from the PET
image, and the amount of IO in the 22Rv1 tumor was calculated
to be 0.0825 μg.
Based on these imaging studies, it was demonstrated that MR
images show a higher resolution of tumor uptake, and PET
Figure 7. In vivo micro MRI image results. (A) Before injection, control image; (B) after injection of DOTA-IO-GUL (0.1 mL, 0.2 mM) through the tail vein
(1 h). Left tumor is PSMA positive (22Rv1) and right tumor is PSMA-negative (PC-3). Red circle demonstrates the selective uptake of DOTA-IO-GUL to the
positive tumor (49.1 Fe ng/g).
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results of tumor uptake.Discussion
PET/MR dual imaging is an attractive imaging tool for the
next generation of molecular imaging field. MR imaging can
provide high-resolution anatomical imaging, while PET imaging
can provide specific binding and quantitative information. In
addition, PET can provide images with high sensitivity to
microdoses of radioisotopes. Development of an efficient and
reliable PET/MR dual-imaging probe is essential to actualize the
PET/MR instrument's powerful application.
IO-based nanoparticles are one of the best options for a PET/
MR dual imaging probe, especially because the basis of IO is
iron which exists in abundantly in the human body particularly in
blood. Thus, IO NPs are known to be less toxic than a
gadolinium (Gd)-based MR contrast agents.52 In the present
study, DOTA-IO-GUL was prepared by the encapsulation of
oleic acid-coated IO NPs using special amphiphiles such as
GUL-SA, NOTA-SA and polysorbate 60. GUL-SA and
NOTA-SA were easily prepared by organic synthesis.
GUL is a specific PSMA-targeting moiety. Prostate cancer is
now one of the most rapidly increasing types of cancer
worldwide. Thus the necessity of dual-modal imaging probes
like DOTA-IO-GUL for early and accurate diagnosis of prostate
cancer is extremely high.
The uptake of NPs by tumors is often associated with the
enhanced permeability and retention (EPR) effect, which can
occur with nanoparticles to any kind of tumors, non-
specifically.53-55 However, in this study, we used a PSMA-
positive and PSMA-negative tumor xenografted mouse model to
prove the specificity. Uptake of DOTA-IO-GUL was revealed
only in the PSMA-positive tumor by both PET and MR imaging.
If the DOTA-IO-GUL uptake by the tumor was by the EPR
effect, the uptake might be exhibited in both the PSMA-positive
and negative tumors. We also proved by PET imaging that the
uptake of DOTA-IO-GUL could be blocked by a PSMA-binding
agent, which definitely demonstrated that the uptake was specific
but not EPR effect.In this experiment, we could distinguish the specific uptake of
DOTA-IO-GUL to the PSMA-positive tumor by MR imaging by
using a mouse model xenografted with both PSMA-positive and
negative tumors, and MR images were obtained both before and
after administration of DOTA-IO-GUL. However, in clinical
settings, MR imaging would produce gray tumor images which
would make it almost impossible to distinguish whether it is
positive or not. Thus, the cancer specificity can be provided only
by PET imaging, but not by MR imaging in clinical practice.
Another important point to consider about the PET/MR
dual-imaging agent is the different sensitivities of PET and MRI.
One of the most important advantages of PET is its high
sensitivity, thus microdosing of the contrast agent is enough to
obtain high quality imaging.56 On the other hand, due to its low
sensitivity, a much higher dose of contrast agent is required for
MR imaging than PET. In order to solve this problem, microdose
of 68Ga-DOTA-IO-GUL having a high enough radioactivity
(10.2 MBq) was used for PET imaging and cold DOTA-IO-GUL
having enough concentration for MRI contrast agent (0.2 M)
was used for MR imaging in this study. Thus, we could obtain
both PET and MR images successfully.
Although PET can provide us with highly specific images, it
tends to produce images with low resolution. Positron emitters
can travel a few millimeters before annihilation occurs, which is
a cause of decreasing resolution. In addition, the partial volume
effect also affects resolution especially in small objects. These
are intrinsic problems of PET imaging, which can be
compensated by a simultaneous MRI or CT.
Furthermore, DOTA-IO-GUL can be labeled not onlywith 68Ga
but also with therapeutic beta emitters such as 90Y or 177Lu which
have low penetration and high cytotoxic effects. Therefore, it has
possibility of being used for theranostic application in the future.
In summary, we prepared a PSMA-targeting IO NP as a PET/
MR dual-imaging probe by a straightforward and reliable
method: encapsulation of NPs with specially prepared amphi-
philes. Additionally, this method can be easily and widely used
for many other diseases and targeting biomarkers by targeting-
moiety introduced specific amphiphiles.
The prepared NP, 68Ga-DOTA-IO-GUL, showed high
radiolabeling efficiency at pH 5.6 and was stable in high-salt
concentration. The specific binding of 68Ga-DOTA-IO-GUL to
Figure 8. In vivo PET result. (A) PSMA-selective uptake result in micro PET imaging. (SUVmean = 0.668)
68Ga-DOTA-IO-GUL (10.2 MBq, 0.1 mL) tail vein
injection after 1 h imaging. Left tumor is PSMA-positive (22Rv1) and right tumor is PSMA-negative (PC-3). (B) Blocking study result with co-injection of
MIP-1072 (50 mg/kg).
878 S.-H. Moon et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 871–879PSMA-positive cells was confirmed in vitro and in vivo. PET/
MR dual images were successfully obtained by using an
adequate amount of radioactivity and cold NPs to adjust the
sensitivity of each modality. MR images showed a high uptake of
the NP by the PSMA-positive tumor with high resolution, but
were limited in providing quantitative information. PET images
also showed specific uptake by the PSMA-positive tumor, and
furthermore provided quantitative information. With this infor-
mation, the amount of IO NP accumulated in the tumor could
be calculated. However, the resolution of PET images was
lower than the MR images. In conclusion, 68Ga-DOTA-IO-GUL
has shown to be a promising dual-modal agent for the imaging
of prostate cancer, with the complementary effects of each
imaging modality.
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